Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases
P. Mandal, Anindya Adhikari, Subir Biswas, A. Giri, Arnab Gupta, A. Bhattacharya
{"title":"Comparison of histopathological grading and staging of breast cancer with p53-positive and transforming growth factor-beta receptor 2-negative immunohistochemical marker expression cases","authors":"P. Mandal, Anindya Adhikari, Subir Biswas, A. Giri, Arnab Gupta, A. Bhattacharya","doi":"10.4103/ctm.ctm_4_20","DOIUrl":null,"url":null,"abstract":"Background: Immunohistochemical analysis of biomarkers is essential to understand the nature of breast cancer (BC) and predict its prognosis. A noticeable correlation is found between p53-positive and transforming growth factor-beta receptor 2 (TGFBR-2)-negative immunomarker expression in BC cases. Materials and Methods: Between January 2018 and December 2018, immunohistochemical analysis of p53 and TGFBR-2 biomarkers was done in biopsy samples from 50 BC cases (49 females and 1 male). Results: p53 expression was positive in 24 (48%) and negative in 26 (52%) cases. Similarly, TGFBR-2 expression was positive in 26 (52%) and negative in 24 (48%) cases. Among p53-positive cases, 8 (16%), 15 (30%), and 1 (2%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Among TGFBR-2-negative cases, 9 (18%), 13 (26%), and 2 (4%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Further, Grade 2 cancer cases were found mostly associated with both p53-positive and TGFBR-2-negative cases. Maximum p53positive cases was in T2N1Mx stage while maximum TGFBR-2-negative cases were in T2N0Mx stage. Conclusion: p53-positive and TGFBR-2-negative cases are mostly associated with Grade 2 and T2 stage of BC.","PeriodicalId":9428,"journal":{"name":"Cancer Translational Medicine","volume":"1 1","pages":"30 - 33"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Translational Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ctm.ctm_4_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Immunohistochemical analysis of biomarkers is essential to understand the nature of breast cancer (BC) and predict its prognosis. A noticeable correlation is found between p53-positive and transforming growth factor-beta receptor 2 (TGFBR-2)-negative immunomarker expression in BC cases. Materials and Methods: Between January 2018 and December 2018, immunohistochemical analysis of p53 and TGFBR-2 biomarkers was done in biopsy samples from 50 BC cases (49 females and 1 male). Results: p53 expression was positive in 24 (48%) and negative in 26 (52%) cases. Similarly, TGFBR-2 expression was positive in 26 (52%) and negative in 24 (48%) cases. Among p53-positive cases, 8 (16%), 15 (30%), and 1 (2%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Among TGFBR-2-negative cases, 9 (18%), 13 (26%), and 2 (4%) cases correlated with histologic Grade 1, Grade 2, and Grade 3 cases, respectively. Further, Grade 2 cancer cases were found mostly associated with both p53-positive and TGFBR-2-negative cases. Maximum p53positive cases was in T2N1Mx stage while maximum TGFBR-2-negative cases were in T2N0Mx stage. Conclusion: p53-positive and TGFBR-2-negative cases are mostly associated with Grade 2 and T2 stage of BC.